BioClinica has posted a net income of $497000 for the second quarter 2010, or $0.03 per diluted share, compared to $529000, or $0.04 per diluted share, for the comparable period in 2009.
For the six months ended June 30, 2010, BioClinica has posted revenue of $37.5m compared to $34.13m for the year ago period.
BioClinica has further reported a net income of $1.20m, or $0.08 per diluted share, compared to $1.32m, or $0.09 per diluted share, for the year ago period.
Mark Weinstein, CEO of BioClinica, said: “While we are seeing improvements in overall market activity, and are pleased to report backlog increased 10.7% year over year, we continue to experience delays in contract executions and project starts relative to signings.
“As a result, we now expect our second half results will be sequentially flat with our first half results, and are therefore narrowing our full year service revenue guidance to $61 to $63m, and lowering our full year non-GAAP EPS to be in the range of $0.25 to $0.30 per share and correspondingly our GAAP EPS to be in the range of $0.15 to $0.20 per share.”
BioClinica supports medical device and pharmaceutical companies with imaging core lab, internet image transport, electronic data capture, interactive voice and web response, Microsoft Office-Smart clinical trial management, and clinical supply chain forecasting and optimization solutions.
